Efficacy News and Research

RSS

Study highlights need for measures to improve annual lung cancer screening adherence

A study from the Thoracic Oncology Research Group, Division of Pulmonary Critical Care, Medical University of South Carolina aimed to examine the adherence to annual low-dose computed tomography screening after baselines LDCT within the Veteran Health Administration Lung Cancer Screening Demonstration Project.

1 Oct 2018

Cancer drug trials focus on progression-free survival and overlook health-related quality of life

A McMaster University-led review and analysis of randomized clinical trials is questioning whether interventions which prolong progression-free survival in cancer patients, improve their health-related quality of life.

1 Oct 2018

Aspirin shown to prevent the spread of cancer

New research by Cardiff University has demonstrated a role for Aspirin in the treatment of bowel, prostate and breast cancer.

1 Oct 2018

Researchers identify genes that could help predict treatment outcomes for parasitic disease

Researchers at the University of York have identified genes in a parasite that could help clinicians predict drug treatment outcomes for patients with visceral leishmaniasis in Brazil.

1 Oct 2018

International conference features cutting-edge research studies on cancer immunotherapy

The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.

1 Oct 2018

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration for an indication expansion for Eisai's antiepileptic drug Fycompa (perampanel) to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older.

1 Oct 2018

$Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors$

Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors

A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to data presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of patients with the disease who do not respond to conventional treatment.

29 Sep 2018

Specially-designed wearable devices have potential to inform research into selective mutism

In a new study published in the journal Frontiers in Psychiatry, a team led by Child Mind Institute researchers found that specially-designed wearable devices that passively capture and quantify child vocalization features have the potential to inform research into selective mutism by providing standardized, objective measurements that can aid in diagnosis and assess the efficacy of treatment approaches.

29 Sep 2018

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

28 Sep 2018

Synthetic DNA vaccine targets proteins overexpressed in several types of cancer

Scientists at The Wistar Institute have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.

28 Sep 2018

Rochester and Minnesota team receives grant to create center for child maltreatment studies

The University of Rochester's Mt. Hope Family Center, in conjunction with the University of Minnesota's Institute for Translational Research in Children's Mental Health, has received a multi-million-dollar grant to create a national center for child maltreatment studies, becoming one of only three academic institutional partnerships in the United States to receive this prestigious award from the National Institutes of Health.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

BioAxone BioSciences, Inc. announced today the receipt of a Fast-Track grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, as part of the agency's Small Business Innovation Research Program.

27 Sep 2018

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

UCI School of Medicine researchers have been awarded a $3.4 million grant by the National Cancer Institute as part of the Beau Biden Cancer Moonshot initiative.

27 Sep 2018

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

New cell-based profiling service from RBC and Promega

A new cell-based profiling service for drug discovery has been announced by RBC and Promega Corporation.

From Promega Corporation 27 Sep 2018

Hope for paraplegics in the horizon

According to a new study from the University of Louisville, four paraplegics have found hope. Paraplegia is complete paralysis of the lower limbs due to damage or injury to the spinal cord. The team of researchers have published their success story in a study in the latest issue of the New England Journal of Medicine.

26 Sep 2018

Efficacy News and Research

Study highlights need for measures to improve annual lung cancer screening adherence

Cancer drug trials focus on progression-free survival and overlook health-related quality of life

Aspirin shown to prevent the spread of cancer

Researchers identify genes that could help predict treatment outcomes for parasitic disease

International conference features cutting-edge research studies on cancer immunotherapy

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

Specially-designed wearable devices have potential to inform research into selective mutism

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

Synthetic DNA vaccine targets proteins overexpressed in several types of cancer

Rochester and Minnesota team receives grant to create center for child maltreatment studies

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

New cell-based profiling service from RBC and Promega

Hope for paraplegics in the horizon

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News